Search Weight Loss Topics:

Page 807«..1020..806807808809..820830..»

Home » Page 807

Miniature fitness trackers for lobsters and devices to monitor the quality of their shipping conditions are being prototyped as part of an initiative to reduce stress points and improve survival in the lobster supply chain for the Maine lobster industry.

The University of Maine Lobster Institute leads the initiative in collaboration with lobster industry partners and scientific collaborators at Saint Josephs College and Wells National Estuarine Research Reserve. This effort to improve practices to reduce mortality throughout the lobster supply chain was one of 30 projects nationwide to receive funding earlier this year from the National Oceanographic and Atmospheric Administration Saltonstall-Kennedy Program. Of the eight funded projects in the Atlantic region, it is the only one focused on the American lobster.

Maines lobster industry asked the institute to help quantify and mitigate stress points in the lobster supply chain that reduce survival and profitability, says Lobster Institute director Rick Wahle, who is based at UMaines Darling Marine Center. The industry calls it shrink the mortality lobsters experience as they change hands from capture to kitchen. Its been a long-standing, contentious issue that is heating up, both literally and figuratively, in a changing climate and competitive world market.

As part of the two-year project funded at more than $299,000, miniature sensory devices crustacean heart and activity trackers (C-HAT, pronounced sea-hat) are being prototyped. Comparable to a human fitness tracker, the noninvasive device strapped on a lobster is designed to monitor heart rate and movement as the crustacean passes from trap to on-board live tank to live storage crate to truck to wholesaler or processor.

A separate sensor-equipped device called the MockLobster will also travel along with crated lobsters to log environmental conditions experienced, including temperature, light and dissolved oxygen.

The idea is to strap the C-HAT on a lobster in a crate as a representative of how a lobster responds to the trip from boat to wharf to wholesaler and to its final destination, says Ben Gutzler of Wells National Estuarine Research Reserve, who is collaborating on the devices along with Steve Jury of Saint Josephs College. Ideally, we will also have a MockLobster traveling with the C-HAT to measure temperature, motion and other conditions, as the crate makes the trip. Well then do it all over again for more trips, so we have a representative sampling of trips from a particular wharf.

Concurrently, UMaine researchers are working with harvesters and dealers to develop an economical, standardized protocol to monitor water quality and the health of lobsters as they move from trap to boat wells to live tanks on wharfs and inland storage facilities.

Andrew Goode, a UMaine Ph.D. student in oceanography and a lobsterman from Boothbay, and Cassie Leeman, a masters student in marine biology, have been undertaking the initial setup for monitoring, data collection and analysis in collaboration with working supply chain companies, such as Ready Seafood and Lukes Lobster, both members of the Maine Lobster Dealers Association. The initial work was catalyzed by a one-year, $35,000 2019 Graduate Assistantship Award to Goode from the University of Maine System Research Reinvestment Fund.

The project aims to track both conditions and lobster health through the supply chain. Goodes and Leemans academic adviser, Damian Brady, UMaine assistant professor of marine sciences who also is based at the Darling Marine Center, is a co-investigator on the project; his focus is on monitoring and mitigating the conditions that lobster experience as they move from trap to dealer. At the same time, co-investigator Deborah Bouchard, UMaine Aquaculture Research Institute director, is leading the development of protocols to monitor lobster health along the way, including behavior, blood proteins, and other physiological indicators.

By developing and implementing quality-control mechanisms, and defining best practices, the researchers and industry leaders seek to address the longstanding issue of mortality in the lobster supply chain that is becoming an even greater concern with the large volume of lobster handled by the fishery, the changing climate and increasingly competitive global markets.

The goal is to improve handling practices to minimize waste and make more efficient use of the natural resource, according to the science-industry team members, including the Maine Lobster Dealers Association and Maine Lobstermens Association.

Identifying and mitigating stress points along the supply chain can mean millions of dollars of savings and avoid waste for the lobster industry, says Curt Brown of Ready Seafood in Portland and Saco. Live lobster dealers, processors and pound owners typically experience shrink rates ranging anywhere from 3% to as much as 20%. For an annual harvest valued at nearly half a billion dollars, this level of loss could equate to as much as $100 million.

The Maine Lobster Dealers Association and the Maine Lobstermens Association have been the driving forces in the project, Wahle says. We are making a collective effort to bring new technology to bear to address stress points as lobsters change hands multiple times in their trip from trap to table. If we can demonstrate that we have the tools to track the fate of lobsters through the supply chain and enhance their survival, that will be a success.

The Lobster Institute, in UMaines College of Natural Sciences, Forestry, and Agriculture, has been working with the lobster industry since 1987. Its mission is to foster collaboration and communication in support of a sustainable and profitable lobster industry in the Northeast U.S. and Canada. More information is online.

Read more:
Fitness trackers, environmental sensors prototyped to improve survival in the lobster supply chain - Boothbay Register

Read More..

In an effort to stay fit and sane in these trying times, Americans have become especially innovative when it comes to finding ways to exercise during the pandemic.

With quarantines and stay-at-home mandates prompting temporally closures at many gym chains and fitness boutiques around the country, Americans have turned to new ways to get their blood pumping. Some are equipping their own at-home studios with Peloton bikes and NordicTrack treadmills, leading to massive sales booms and weeks-long back orders, while others are unfurling their yoga mats and queuing up virtual streaming classes from their favorite instructors.

In areas where gyms have started to slowly reopen to the public, companies are enforcing new policies including mandating masks, reducing capacity, and enhancing sanitizing, while others are ignoring protocols altogether and defying state mandates at "speakeasy gyms."

We took a closer look at some of the biggest trends in fitness as the pandemic continues on.

Read the rest here:
12 ways the pandemic has changed fitness and exercise as we know it - Business Insider - Business Insider

Read More..

Amazon is getting into the health gadget market with a new fitness band and subscription service called Halo. Unlike the Apple Watch or even most basic Fitbits, the Amazon Halo Band doesnt have a screen. The app that goes along with it comes with the usual set of fitness tracking features along with two innovative and potentially troubling ideas: using your camera to create 3D scans for body fat and listening for the emotion in your voice.

The Halo Band will cost $99.99 and the service (which is required for Halos more advanced features) costs $3.99 per month. Amazon is launching it as an invite-only early access program today with an introductory price of $64.99 that includes six months of the service for free. The Halo service is a separate product that isnt part of Amazon Prime.

The lack of a screen on the Halo Band is the first indicator that Amazon is trying to carve out a niche for itself thats focused a little less on sports and exercise and a little more on lifestyle changes. Alongside cardio, sleep, body fat, and voice tone tracking, a Halo subscription will offer a suite of labs developed by partners. Theyre short challenges designed to improve your health habits like meditation, improving your sleep habits, or starting up basic exercise routines.

The Halo Band is not a medical device, Amazon tells me. As such, it hasnt submitted the device to the FDA for any sort of approval, including the lighter-touch FDA clearance that so many other fitness bands have used.

The Amazon Halo intro video. | Source: Amazon

The Halo Band consists of a sensor module and a band that clicks into it on top. Its a simple concept and one weve seen before. The lack of a display means that if you want to check your steps or the time, youll need to strap something else to your wrist or just check your phone.

The band lacks increasingly standard options like GPS, Wi-Fi, or a cellular radio, another sign that its meant to be a more laid-back kind of tracker. It has an accelerometer, a temperature sensor, a heart rate monitor, two microphones, an LED indicator light, and a button to turn the microphones on or off. The microphones are not for speaking to Alexa, by the way, theyre there for the voice tone feature. There is explicitly no Alexa integration.

It communicates with your phone via Bluetooth, and it should work equally well with both iPhones and Android phones. The three main band colors that will be sold are onyx (black), mineral (light blue), and rose gold (pink-ish).

There will of course be a series of optional bands so you can choose one to match your style and all of them bear no small resemblance to popular Apple Watch bands. The fabric bands will cost $19.99 and the sport bands will be $15.99.

Amazon intends for users to leave the Halo Band on all the time: the battery should last a full week and the sensor is water resistant up to 5ATM. Amazon calls it swimproof.

But where the Halo service really differentiates itself is in two new features, called Body and Tone. The former uses your smartphone camera to capture a 3D scan of your body and then calculate your body fat, and the latter uses a microphone on the Halo Band to listen to the tone of your voice and report back on your emotional state throughout the day.

Body scans work with just your smartphones camera. The app instructs you to wear tight-fitting clothing (ideally just your underwear) and then stand back six feet or so from your camera. Then it takes four photos (front, back, and both sides) and uploads them to Amazons servers where theyre combined into a 3D scan of your body thats sent back to your phone. The data is then deleted from Amazons servers.

Once you have the 3D scan, Amazon uses machine learning to analyze it and calculate your body fat percentage. Amazon argues that body fat percentage is a more reliable indicator of health than either weight or body mass index. Amazon also claims that smart scales that try to measure body fat using bioelectrical impedance are not as accurate as its scan. Amazon says it did an internal study to back up those claims and may begin submitting papers to peer-reviewed medical journals in the future.

Finally, once you have your scan, the app will give you a little slider you can drag your finger on to have it show what you would look like with more or less body fat.

That feature is meant to be educational and motivational, but it could also be literally dangerous for people with body dysmorphic disorder, anorexia, or other self-image issues. I asked Amazon about this directly and the company says that it has put in what it hopes are a few safeguards: the app recommends you only scan yourself every two weeks, it wont allow the slider to show dangerously low levels of body fat, and it has information about how low body fat can increase your risk for certain health problems. Finally, although anybody 13 years of age and up can use the Halo Band, the body scan feature will only be allowed for people 18 or older.

The microphone on the Amazon Halo Band isnt meant for voice commands; instead it listens to your voice and reports back on what it believes your emotional state was throughout the day. If you dont opt in, the microphone on the Band doesnt do anything at all.

Once you opt in, the Halo app will have you read some text back to it so that it can train a model on your voice, allowing the Halo Band to only key in on your tone and not those around you. After that, the band will intermittently listen to your voice and judge it on metrics like positivity and energy.

Its a passive and intermittent system, meaning that you cant actively ask it to read your tone, and its not listening all of the time. You can also mute the mic at any time by pressing the button until a red blinking LED briefly appears to show you its muted.

Amazon is quick to note that your voice is never uploaded to any servers and never heard by any humans. Instead, the band sends its audio snippets to your phone via Bluetooth, and its analyzed there. Amazon says that the Halo app immediately deletes the voice samples after it analyzes them for your emotional state.

It picks up on the pitch, intensity, rhythm, and tempo of your voice and then categorizes them into notable moments that you can go back and review throughout the day. Some of the emotional states include words like hopeful, elated, hesitant, bored, apologetic, happy, worried, confused, and affectionate.

We asked Amazon whether this Tone feature was tested across differing accents, gender, and cultures. A spokesperson says that it has been a top priority for our team but that if you have an accent you can use Tone but your results will likely be less accurate. Tone was modeled on American English but its only day one and Tone will continue to improve.

Both the Body and Tone features are innovative uses of applied AI, but they are likely to set off any number of privacy alarm bells. Amazon says that it is being incredibly careful with user data. The company will post a document detailing every type of data, where its stored, and how to delete it.

Every feature is opt-in, easy to turn off, and its easy to delete data. For example, theres no requirement you create a body scan and even if you do, human reviewers will never see those images. Amazon says the most sensitive data like body scans and Tone data are only stored locally (though photos do need to temporarily be uploaded so Amazons servers can build the 3D model). Amazon isnt even allowing Halo to integrate with other fitness apps like Apple Health at launch.

Some of the key points include:

The body scanning and tone features might be the most flashy (or, depending on your perspective, most creepy) parts of Halo, but the thing youll likely spend the most time watching is your activity score.

Amazons Halo app tracks your cardio fitness on a weekly basis instead of daily allowing for rest days. It does count steps, but on a top level, what you get is an abstracted score (and, of course, a ring to complete) thats more holistic. Just as Google did in 2018, Amazon has worked with the American Heart Association to develop the abstracted activity score.

The Halo Band uses its heart monitor to distinguish between intense, moderate, and light activity. The app combines those to ensure youre hitting a weekly target. Instead of the Apple Watchs hourly stand prompts, the Halo app tracks how long you have been sedentary. If you go for more than eight hours without doing much (not counting sleep), the app will begin to deduct from your weekly activity score.

The Halo Band can automatically detect activities like walking and running, but literally every other type of exercise will need to be manually entered into the app. The whole system feels less designed for workout min-maxers and more for people who just want to start being more active in the first place.

Speaking of heart tracking, the Halo Band doesnt proactively alert you to heart conditions like atrial fibrillation, nor does it do fall detection.

The Halo Bands sleep tracking similarly tries to create an abstracted score, though you can dig in and view details on your REM sleep and other metrics. One small innovation that the Halo Band shares with the new Fitbit is temperature monitoring. It uses a three-day baseline when you are sleeping and from there can show a chart of your average body temperature when you wake up.

Finally, Amazon has partnered with several third parties to create services and studies to go along with the Halo service. For example, if your health care providers system is compatible with Cerner, you can choose to share your body fat percentage with your providers electronic medical records system. Amazon says it will also be a fully subsidized option for the John Hancock Vitality wellness program.

The flagship partnership is with WW, which syncs up data from Halo into WWs own FitPoints system. WW will also be promoting the Halo Band itself to people who sign up for its service.

There are dozens of lower-profile partnerships, which will surface in the Halo app as Labs. Many of the labs will surface as four-week challenges designed to get you to change your health habits. Partners creating Labs range from Mayo Clinic, Exhale, Aaptiv, Lifesum, Headspace, and more. So there might be a lab encouraging you to give yoga a try or a set of advice on sleeping better like kicking your pet out of your bedroom.

Amazon says each Lab needs to be developed with scientific evidence of its effectiveness and Amazon will audit them. Data created from these challenges will be shared with those partners but only in an aggregated, anonymous way.

Virtually all the features discussed here are part of the $3.99 / month Halo subscription. If you choose to let it lapse, the Halo Band will still do basic activity and sleep tracking.

In charging a monthly subscription, Amazon is out on a limb compared to most of its competitors. Companies like Fitbit and Withings offer some of the same features you can get out of the Halo system, including sleep tracking and suggestions for improving your fitness. They also have more full-featured bands with displays and other functionality. And of course theres the Apple Watch, which will have deeper and better integrations with the iPhone than will ever be possible for the Halo Band.

Overall, Halo is a curious mix. Its hardware is intentionally less intrusive and less feature-rich than competitors, and its pricing strategy puts Amazon on the hook for creating new, regular content to keep people subscribed (exercise videos seem like a natural next step). Meanwhile, the body scanning feature goes much further than other apps in directly digitizing your self-image which is either appealing or disturbing depending on your relationship to your self-image. And the emotion tracking with Tone is completely new and more than a little weird.

The mix is so eclectic that I cant possibly guess who it might appeal to. People who are more serious about exercise and fitness will surely want more than whats on offer in the hardware itself, and people who just sort of want to be a little more active may balk at the subscription price. And since the Halo Band doesnt offer the same health alerts like fall detection or abnormal heart rate detection, using it as a more passive health monitor isnt really an option either.

That doesnt mean the Halo system cant succeed. Amazons vision of a more holistic health gadget is appealing, and some of its choices in how it aggregates and presents health data is genuinely better than simple step counting or ring completion.

We wont really know how well the Halo system does for some time, either. Amazons opening it up as an early access program for now, which means you need to request to join rather than just signing up and buying it.

Go here to read the rest:
Amazon Halo: a fitness band and app that scans your body, listens to your voice - The Verge

Read More..

Richard Decker, founder of AWATfit, is looking to bring his mobile gym to Bergen County for those looking to get a workout in an outdoor space. NorthJersey.com

While the gym industry has struggled during the pandemic, oneentrepreneur is bringing the gym straight to the great outdoors.

Richard Deckerdidn't createAWATfit in response to coronavirus pandemic; it was only a bit of luck that saw him putting the finishing touches on his new mobile gym model last year.

The New York-based business, which is now looking to expand to Bergen County,has thrived as people have looked for a safe way to get their daily exercise routine.

Richard Decker, CEO and founder of AWATfit, stands on his truck, the centerpiece of his mobile gym business.(Photo: Photo courtesy of Aaron Kresberg)

"What COVID did was quadruple my business,"said Decker."We were the only gym that wasnt closed down. We would work out right next to the code enforcers."

Decker beganlooking into creating AWATfit, which stands for"Any Where, Any Time,"in 2018 after walking away from the brick and mortar gym and restaurant industry after 30 years. Creating a fitness model where he wasnt attached to a physical location and at the mercy of landlords appealed to him, leading him to start doing personal training for customers in outdoor environments such as nature trails.

Richard Decker, CEO and founder of AWATfit, helps customers work out with bungee cords as part of his mobile gym.(Photo: Photo courtesy of Aaron Kresberg)

Studies have shown that being outdoors can help lower blood pressure andstress hormone levels, improve immune systems and help reduce anxiety, said Tracy Scheller, medical director of Englewood Healths Graf Center for Integrative Medicine. One scientific study conducted last year has shown that those who spend at leasttwo hours per week in green spaces were more likely to have good mental and physical health, Scheller said.

"Now youre getting the benefit of this exercise and a gym while also having the benefit of being in nature,"said Scheller. "A lot of gyms have windows and you can see the trees, but actually being outside has really shown some real benefit."

After hearing from customers that they may not want to exercise in the woods during the summer months, when ticks are active, Decker looked into getting a truck that would provide him with a means to bring his business wherever a customer wants him.

The truck, which started serving customers in New York in February 2019, can allow25 customers at a time, who use equipment such as pull-up bars, chin-up bars, heavy bags, suspension training, slam balls and bungee cords that connect directly to the truck.

Before the pandemic, Decker had begun franchising, sending trucks to Westchester County,Long Islandand Texas. Now, in addition to Bergen County, hes looking to expand the business to Florida and California.

"Pre-COVID, I would be like, 'I dont know how were going to get to these areas,'but post-COVID, the areas are coming to us,"said Decker.

He said AWATFIT cost about $100,000 to start up, truck included, while his last 4,000-square-foot physical gym cost about $750,000.

Decker islooking to partner with organizations trying to fundraiser during the pandemicby donating a part of the proceeds for the fitness classes.

One of his goals is helping to raise $25,000 for playground equipment in Mashashimuet Park in his hometown of Sag Harbor, New York.

Even though gyms are beginning to reopen,Decker said customers might not be rushing back to their local gyms right away, which will put additional strain on the industry.

FITNESS: NJ gym owners are eager to welcome members back as Murphy says gyms can reopen next week

DINING: NJ restaurant owners and local officials make their case for indoor dining

COVID-19: Coronavirus vaccine trial: Two New Jersey hospitals are looking for volunteers

"People dont want to go indoors,"said Decker. "They are afraid to go indoors. Even though the gyms are opening, there are all these restrictions."

Indoor gyms will reopen in New Jersey at25% capacity on Sept. 1 with rules including temperature screenings, masks and social distancing (gym users must stay six feet apart at all times). Members must also wear their workout clothes instead of changing in a locker room.

Decker said he was happy that he left behind the world of brick and mortar gym and restaurants behind and had set up his mobile, outdoor business before the pandemic. He said he worries for his friends that are in the industry.

"Both of those businesses are never going to come back the same and those that are in, unless they have a huge corporate sponsor, they are not going to make it through it," he said.

Stephanie Nodais a local reporter for NorthJersey.com. For unlimited access to the most important news from your local community,please subscribe or activate your digital account today. Email:noda@northjersey.comTwitter:@snoda11

Read or Share this story: https://www.northjersey.com/story/news/business/2020/08/30/gym-owner-awatfit-says-covid-pandemic-favors-outdoor-fitness/5647455002/

Excerpt from:
Mobile gym owner says open-air fitness is way of the future - NorthJersey.com

Read More..

Jade Rammell, Pocatello native, competing to be on the cover of Ms. Health & Fitness. | Julian Paras, KPVI

POCATELLO (KPVI) If you were to ask Jade Rammell how fitness has affected her life, she would say its had a domino effect that has made her life better.

The Pocatello native is now competing to be on the next cover of Ms. Health & Fitness.

Getting to this point has been a three year journey and it isnt something she would have looked forward to back then. It took a lot of work to get to where she is today, and postpartum depression was one of her biggest challenges along the way.

I wasnt myself. I cried all the time. I had dark thoughts. I was very short-tempered. I was just mean and I just wasnt myself, Rammell says.

Taking medication to combat her depression has always been part of her daily routine, but the thing thats made the biggest difference for her is movement.

Its really nice to know that movement is medicine. It helps you out a lot, she says. Id come home feeling a million times better. Id be happier. Id be ready to get my to-do list done and it just helped a lot.

With this competition, she hopes shes also setting an example for her young daughter, who is already following in mothers footsteps.

She loves to play with the weights and grab on to them. She cant lift them at all but she loves to be around it, says Rammell.

Overall, Rammell says fitness has done more for her than just being fit. Its also helped her be open to new experiences and where they can take her.

The competition ends Sunday at 11 p.m. and shes asking for your supporting vote here.

Link:
Local mom has used fitness to push through life struggles, and now she's in a national competition - East Idaho News

Read More..

Photo by Andrew Bowen

Above: The exterior of Boulevard Fitness is seen here on Aug. 26, 2020.

Boulevard Fitness, the University Heights gym that made national news for its refusal to shut down despite orders to do so from county health officials, is temporarily closing its doors.

In an email to gym members Wednesday, owner Shawn Gilbert said recent enforcement actions from the county health department and San Diego Police Department made its continued unlawful operations unsustainable.

"We have been fighting hard and doing everything we can to continue to keep our doors open for all of our members but due to current fiscal situations we have to temporary (sic) close our doors," the email read. "Unfortunately, the fines that we are looking at getting would prevent the business from being open on the other side of this closure."

The email to members came one day after the San Diego City Attorney's Office sent Gilbert a letter threatening legal action that could result in fines of up to $2,500 per day.

As of around 4 p.m. Wednesday, people were still working out in the gym, but those trying to enter were being turned away.

RELATED: Why One Business Owner Decided To Follow Health Rules While Some Of His Competitors Arent

San Diego County was ordered to close indoor operations at all gyms in mid-June due to a spike in COVID-19 infections. While the vast majority of gyms and other businesses in the county have complied with those orders, Boulevard Fitness has stayed open.

County officials later moved to toughen up enforcement against rogue businesses, but it wasn't until Aug. 11 that SDPD issued a citation to the gym's owner.

Gilbert said the gym would continue to charge members their monthly fee during the closure unless they request that it be suspended "to ensure that there is a great gym available for you on the other side of this closure."

"We appreciate all of you who are willing and able to continue billing during our closure and recognize that not everyone has the financial means to do so," the email said. "Please note that September 1st billing is right around the corner and we may not be able to delay that one dependent on when we get the email."

San Diego County was removed from the state watch list last week due to improving COVID-19 figures, but it remains unclear whether the state will allow gyms to reopen for indoor activities. Outdoor gyms have been allowed, but not all gyms have had the space or budget to make that transition.

KPBS' daily news podcast covering local politics, education, health, environment, the border and more. New episodes are ready weekday mornings so you can listen on your morning commute.

Andrew Bowen Metro Reporter

I cover local government a broad beat that includes housing, homelessness and infrastructure. I'm especially interested in the intersections of land use, transportation and climate change.

To view PDF documents, Download Acrobat Reader.

Read more:
After Months Of Defying COVID-19 Health Order, Boulevard Fitness To Close - KPBS

Read More..

The Xiaomi Mi Band 5 is a petite fitness tracker

The Xiaomi Mi Smart Band 5 is a cheap fitness tracker. It costs $50, or around 35 in the UK.

This band is significantly more affordable than the Fitbit Inspire HR or Samsung Galaxy Fit, and even undercuts the otherwise great value Huawei Band 4 Pro.

Is the Xiaomi Mi Smart Band 5 too good to be true? For the most part, it is not. However, there are some weaker parts to consider.

This review will break down the positives before switching to the negative Xiaomi Mi Smart Band 5 elements, and then a look at some of its additional features.

Want the quick verdict? The Xiaomi Mi Smart Band 5 is a great value tracker for those short on funds.

The Xiaomi Mi Smart Band 5 does not have its own GPS chip, but it does have Connected GPS. This uses the location data from your phone to provide accurate distance stats, and maps for your runs and rides.

This is important, as the bands accelerometer-derived estimates are not particularly accurate when running. Connected GPS makes the Xiaomi Mi Smart Band 5 a fair, at the very least, tracker for serious runners.

Just make sure its setup before you start running: the process isnt as seamless as other Connected GPS devices.

It is not the thinnest band, but is smaller than a smartwatch

Most cheap fitness bands offers just a few different watch faces. The Xiaomi Mi Smart Band 5 has loads. There are 57 in my review sample.

Three are preloaded, the other 54 can be syncd using the Mi Fit companion app. Some are cringeworthy, but handfuls are not. A new watch face is a quick way to give the band a fresh look every few weeks.

Thousands of additional designs can also be added using third party apps. Xiaomi takes a far more open approach than most, and you get the benefit. The designs are almost limitless, and feature info beyond the basics, such as the step count, heart rate and battery life.

Here are just some of the Mi Band 5's built-in watch faces

The Xiaomi Mi Smart Band 5s battery drained almost strangely slowly to start, seeming only to drop a few per cent each day. This is because a lot of the advanced features are switched off as standard, but its battery life is still excellent with most turned on.

Xiaomi says the tiny 125mAh battery lasts up to 14 days, which seems perfectly believable. You will see shorter battery life if you max out display brightness (needed for outdoors workouts) and look at notifications all through the day. However, advanced features like all-day heart rate tracking dont seem to have a party-ruining effect on stamina.

Expect the Xiaomi Mi Smart Band 5 to last a week of solid use, including some tracked runs, and you wont be disappointed. This beats both the Galaxy Fit and Fitbit Inspire HR.

The Xiaomi Mi Smart Band 5 can receive notifications from any app you like. Emails, Whatsapps and SMS are all invited.

Its vibration motor buzzes as these come in, and the display lights-up. You cant read full emails, as this is a basic tracker rather than a smartwatch, but unread items do stay in a Notifications section until you take a look.

As in the Huawei Band Pro series, notifications handling feels a little fiddly. But it is good enough to let you check email headers and messages without taking out your phone. It ticks off the basics.

You flick up and down on the Xiaomi Mi Smart Band 5s screen to scroll through each of its main functions. Each primary feature gets a page with a colourful icon. I recommend you prune these down, as the 11 homscreens are a few too many to flick through every day.

The Mi Fit phone app lets you choose which get a spot on the interface. Keep it to four or five of the ones you actually use and the Xiaomi Mi Smart Band 5 will feel slicker.

The Xiaomi Mi Smart Band 5 has a 1.1-inch full colour 294 x 126 pixel OLED screen. This is much more advanced than the monochrome display of the Galaxy Fit E. Its very sharp, colourful and the pure black of the OLED panel looks great against the black surround.

The display covering is glass rather than plastic, which is seen in some budget trackers. And maximum brightness is good, with enough power to make the screen clear when you go for a run on a sunny day.

The screen offers OLED black and a curved glass top

Xiaomi claims the Mi Smart Band 5s optical heart rate (PPG) sensor is 50% more accurate than that of the Mi Band 4. The main positive observation in testing is that it responds very quickly to drops in exertion, and fairly quickly to increases.

It also does not have one issue noted in my Samsung Galaxy Watch 3 review, of overestimating your heart rate if you begin tracking during a low-key pre-run warm up.

The Mi Band 5 has a dual-LED PPG heart rate sensor

Does this mean the Xiaomi Mi Smart Band 5 heart rate sensor is better than the Galaxy Watch 3s? No, it does not.

It is more erratic, with the occasional leap to the ~120bpm range when the rate should be around 70bpm. Mid-workout comparisons with the Wahoo Kickr HR chest strap also suggest the Xiaomi Mi Smart Band 5 makes significant use of cadence data to pre-empt actual drops and rises in heart rate.

Heart rate readings dropped more quickly in the Mi Smart Band 5 than the strap, before normalising, when slowing from a run to walking pace. And its actual bpm accuracy is only OK, with fairly frequent differences of 4-8bpm at consistent exertion levels.

It appears to make significant use of HR prediction to patch up the limitations of a basic PPG sensor.

Resting heart rate readings are not handled particularly well either. Rather than waiting for the correct reading, it usually displays a much higher one before locking onto the correct heart rhythm.

However, look back at the Xiaomi Mi Smart Band 5s automatic readings in the Mi Fit app and you shouldnt see too many odd blips where a high resting heart rate has been recorded. The app stores a graph of your heart rate through the day.

The Mi Band 5 doesn't have a standard watch band, typical of an entry-level tracker

The Xiaomi Mi Smart Band 5 is not the most comfortable budget fitness tracker. Its band is a simple silicone affair with a prong and hole mechanism, not a traditional watch type.

However, its the style and shape of the main unit that causes the lingering problem. The body of the Xiaomi Mi Smart Band 5 is largely flat, with a lump that holds the HR sensor.

This means the main points of contact are this HR mound and the back of the strap. Wear it with a fit tight enough for accurate heart rate readings and youll see a pronounced indent in your skin each time you take it off.

The Fitbit Inspire HR and Huawei Band Pro series watches are more comfortable, because the points of contact are larger, spreading the pressure.

The Mi Band 5 is not the most comfy fitness tracker

The Xiaomi Mi Smart Band 5 also lacks an ambient light sensor, used by phones and smartwatches to alter the display brightness to suit your surroundings. Brightness has to be changed manually.

You will need to do this if you want to make the screen visible during outdoors workouts and keep the battery lasting a week or more.

A lack of auto brightness is not surprising in a cheap but otherwise feature-rich tacker. But it should be quicker to alter manually. It takes eight swipes and taps to reach the brightness control, which is about six too many.

A solution? The Xiaomi Mi Smart Band 5 should make a screen brightness control widget. I need to use it far more often than the Weather, Stress, PAI or Breathing shortcuts.

A greater sin: the Xiaomi Mi Smart Band 5 does not have an always-on screen mode. This is absent to ensure fairly good battery life no matter the number of features you have switched on, like 24/7 heart rate sensing. 10 seconds is the maximum screen time-out.

The Mi Band 5 has a great screen, just not an always-on one

However, a fitness tracker should have, at the very least, an always-on screen feature for workouts. Thankfully, there is a mode that turns the display on when you turn wrist to face, and there are customisable sensitivity settings for this.

This flick to wake mode, and the vast majority of its useful extra features, are not switched on as standard.

Until you go into the Mi Fit app and turn then on, the Xiaomi Mi Smart Band 5 seems a little inert. Extras you may want to turn on include notifications, lift-to-wake, SMS alerts, incoming call alerts, activity monitoring, stress monitoring and GPS via the app. More should probably be enabled as standard.

The Mi Fit also features an ad slot, populated by Xiaomi sub-brand Amazfit during testing. Its not what you want to see, or accidentally touch, after paying out for the companys products.

The Chinese version of the Mi Smart Band 5, called the Mi Band 5, has NFC. This is used for wireless payments, but the feature is missing on the international model.

The Mi Smart Band 5 has 11 tracker modes, including running and cycling both inside and outdoors, rowing, yoga, jump rope and "freestyle".

There are some neat specific extras in a few of these. Youll see lengths in the indoors swimming mode, a stroke count in rowing and the number of jumps in rope-skipping.

As the swim mode suggests, the Xiaomi Mi Smart Band 5 is ready for the pool with 50m (5ATM) water resistance too.

Flick through the Xiaomi Mi Smart Band 5s screens and youll see one called PAI. This acts as a point-based indication of your activity level through the span of a week. The idea is you should keep it at 100 or above at all times. You might get on with it, but it doesnt not offer any great insight if you already exercise regularly.

The Xiaomi Mi Smart Band 5 offers the typical sleep tracking experience. Wear the band overnight and youll see your sleep and wake-up times, and a breakdown of your REM, light and deep sleep segments.

This seems no less accurate than the category average, although the testing period was blissfully free of the broken sleep that might highlight missed wakeful periods.

Here's how your nights of sleep are represented in Mi Fit

Theres a stress monitor function too. This grades you using a fairly rudimentary system, most likely based on current heart rate versus normal resting heart rate and heart rate variability. Its not particularly useful as a manual feature to set off. But you can take a look back over the day in the Mi Fit app if you have a stinker of an afternoon and want proof of its awfulness.

Shutter Camera control is the Xiaomi Mi Smart Band 5s one Labs feature. You can set off the camera shutter with a press on the bands display. It works perfectly well, tested with the Moto G Pro.

The one homepage shortcut not turned on as standard is Cycles. This is a period tracking feature, but I havent been able to test it.

The Xiaomi Mi Smart Band 5 also offers basic music control. This is not relayed in one of the primary shortcuts. You have to dig into the menu a little, but it does let you change the track, pause and control volume fairly easily.

None of the little hidden extras are missing either. The Xiaomi Mi Smart Band 5 has alarms, it can be used to keep your phone unlocked and theres a find my phone feature. Very handy.

The Xiaomi Mi Smart Band 5 does a lot for a small amount of money. Its most important extra is Connected GPS, from a fitness tracking perspective.

The heart rate tracker seems to have a highly algorithm-led approach that does not always show you the right reading, but it does a fair job of showing your exertion as long as you dont look too close at the data. And, to be honest, you can only really tell by comparing it to a more accurate chest strap sensor.

Huaweis Smart Band 4 Pro is arguably even better, with built-on GPS and a more comfortable design, but the Xiaomi Mi Smart Band 5 is an excellent choice if every dollar counts.

See the article here:
Xiaomi Mi Smart Band 5 Review: $50 Fitness Tracker With Stacks Of Features - Forbes

Read More..

TUCSON (KVOA) - Pima County residents who have been craving to pump some iron and work up a sweat may have a place to go soon after LA Fitness announced Wednesday that it will begin opening its gyms across Arizona on Thursday.

Back on June 29, Gov. Doug Ducey made the decision to closegyms, bars, nightclubs, water parks and tubing about a month after Arizona's first Stay-At-Home order.

After ajudge ruledthat Arizona gyms should have the opportunity to reopen on Aug. 4, Arizona Department of Health Services released its benchmarks counties need to reach in order to allow businesses, such as gyms and fitness clubs, to resume operations.

ADHS announced Tuesday that Pima, Pinal and Maricopa counties are projected to reach the requirements to allow indoor gyms and fitness centers to open at 25 percent capacity by Thursday.

With this new information, LA Fitness shared that is plans to start reopening its facilities that day.

At this time, LA Fitness officials have not shared at what capacity their gyms will be open or which gyms across Pima County will reopen Thursday.

For more information, visit lafitness.com.

Link:
LA Fitness to begin reopening gyms starting Thursday - KVOA Tucson News

Read More..

Innovative Report on Testosterone Replacement TherapyMarket with Competitive Analysis, New Business Developments, and Top Companies

A perfect mix of quantitative & qualitativeTestosterone Replacement TherapyMarketMarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Testosterone Replacement Therapy Market. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

Prominent players profiled in the study:, AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

Sample Report with Latest Industry Trends @https://grandviewreport.com/sample/21735

This Report Provides an overview of the Testosterone Replacement Therapymarket, containing global revenue,global production, sales, and CAGR.Also describe Testosterone Replacement Therapyproduct scope, market overview, market opportunities, market driving force, and market risks. The forecast and analysis of the Testosterone Replacement Therapymarket by type, application, and region are also presented. The next part of the report provides a full-scale analysis of Testosterone Replacement Therapycompetitive situation, sales, revenue and global market share of major players in the Testosterone Replacement Therapyindustry. The basic information, as well as the profiles, applications, and specifications of products market performance along with Business Overview, are offered.

The key product type of Testosterone Replacement Therapymarket are:, Gels, Injections, Patches

Testosterone Replacement TherapyMarket Outlook by Applications:, Hospitals, Clinics

Geographical Regions:North America, Europe, Central & South America, Asia-Pacific, and the Middle East & Africa, etc.

Get Reasonable Discount on this Premium Report @https://grandviewreport.com/discount/21735

Scope of the Testosterone Replacement TherapyReport:

This report covers the current scenario and growth prospects of the Testosterone Replacement TherapyMarket for the period 2020-2025. The study is a professional and in-depth study with around tables and figures which provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the domain.

Finally, all aspects of the Global Testosterone Replacement TherapyMarket are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and future prospects.

Browse Full[emailprotected]https://grandviewreport.com/industry-growth/Testosterone-Replacement-Therapy-Market-21735

Go here to see the original:
Testosterone Replacement Therapy Market 2020 : Analysis by Geographical Regions, Type and Application Till 2025 - The Daily Chronicle

Read More..

During a virtual Case Base Peer Perspectives event, Eleni Efstathiou, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discussed treatment options for a 57-year-old African American man with nonmetastaic castration resistant prostate cancer (CRPC)

CASE:

October 2016

November 2016

February 2017

October 2019 - Restaging

Targeted OncologyTM: What are your impressions of this case?

Efstathiou: It looks [as though] after he nadired, he quickly recurred with a detectable PSA and a doubling time of 8.6 months. This is a case thats pointing toward the nonmetastatic castration-resistant prostate cancer [CRPC] status. And in the case, we dont have it, but testosterone would be checked, and it is within the castrate levels.

According to the case, this was followed with conventional imaging. This gentleman is now 60 years old in October 2019.

According to the case, the patient refused [radiotherapy]. Having said that, if you look at the data from the phase 3 trials that were done, you would see that 24% of patients who were included, at least in 1, had not been offered any treatment at the beginning, at their diagnosis, even of their primary [tumor]. So its quite impressive that still, to this day, a lot of patients do not get radiation even on the primary [tumor] when it is needed, and it calls for more education. We dont know if these cases were from the European side, the Asia side, or the United States side. Its not exactly granular, but it was disappointing for me to see.

Would you get advanced testing done for this patient?

Ive been sending patients who can [go for PSMA PET] to University of California, Los Angeles, recently, because I believe that Axumin and PSMA, looking at the data, are equally sensitive. However, it appears that PSMA is more specific. Ive had a lot of false positives on PETs. Im not pointing fingers, but its from different places that I got them, so Im not relying on the results. But, for this case, if the Axumin is still lining up in the prostate, then you have a clear move forward. But, to this day, for nonmetastatic CRPC or for PSA-recurring CRPC only, we do not have an indication to do the PET scan. That is in line with these studies being done with conventional imaging, and that can be a concern with approvals.

Now, this man was given conventional imaging, and this is more the standard across the board.

Do you actively pursue germline testing in high-risk disease or metastatic disease?

I was recently on an ad board, and I was speaking to people from Duke University, Mayo Clinic, and the like. Nobody has any systemic approach yet, and its not even routine in most cases. Its up to the physicians, and it can be more taxing that way, I find, because its 1 more thing added and sometimes can be missed. So I hope that in the future it will become as straightforward as doing the PSA, doing the testosterone, and [other processes such as that].

What are your thoughts on the results of this poll? What would you have voted for?

Most seem to have gone for any of the novel hormonal agents. Somebody put down chemotherapy. Somebody else also voted for nilutamide, flutamide, or bicalutamide.

I would go for other.

Seventy-seven percent voted for enzalutamide [Xtandi], apalutamide [Erleada], darolutamide [Nubeqa], or abiraterone [Zytiga].

How would you compare these agents?

Ive been starting to use [darolutamide] recently. Its approval was more recent.

I dont see a big difference between enzalutamide and apalutamide, not only in the fatigue, per se, but also the central nervous system [CNS] effect, which has to do with some extra depression, some extra insomnia, some extra effects that are not trivial. The difference is small [between these 2]. But the claim from the preclinical data was that apalutamide would have less of a CNS impact. Of course, when you test it in humans is when you see the real deal, and more so in the real-world experience.

With enzalutamide, my experience had always been that at least I can draw a line that I can say if a patient is over 70 years old, he may not perform that well. But, more recently, Ive even seen young men not being able to tolerate it.

And, in the case of this patient, I would say that we should all agree that both enzalutamide and apalutamide would be totally contraindicated because of the seizure disorder. So darolutamide is the only path forward.

What about abiraterone?

These [other] 3 drugs have an indication for nonmetastatic CRPC. Would you expect the insurance to go for abiraterone? I would find it hard [to believe the insurance would accept it,] because its not within the indication.

What are the takeaways from this poll?

Essentially, the bottom line is, you dont see any difference in the efficacy between the 3 agents, but you see an advantage in the safety profile.

Im starting to use darolutamide more, and I was reluctant at first. But now that most data are out, I would say I would agree; theres nothing holding me back in that aspect.

CASE (continued)

After shared decision-making, darolutamide was initiated.

What are your thoughts on the choice of darolutamide?

[The PSA doubling time] was a major concern in the beginning and now, as of this ASCO [American Society of Clinical Oncology Annual Meeting], we have overall survival [OS] data that exceed a year in the CRPC space, which has not been shown before.

I dont know how patients tolerate it yet. I gradually started to give it to the first patient, the second, but Ive got about 10 patients who are on it now, so Im getting there. Its a big deal, because I always say that if we havent had the hands-on experience in research or a clinical trial, it hits the market and then youre [deciding], I dont know this drug, Im going to stay with my comfort level. I can use enzalutamide and abiraterone blindfolded, but it looks [as though] darolutamide is going to be pretty easy. I want to see their data.

My only thing is I want to see more data coming from them with regards to bone density, and I think theyre getting ready to give those datathe effects of that antiandrogen. Were also looking forward to getting their hormone-nave data, which is also going to come forth. Theres a trial where investigators are combining it with chemotherapy. So its pretty new; its the new agent, but Im feeling more and more comfortable with it.

What are the data supporting the use of the 3 newest agentsapalutamide, enzalutamide, and darolutamidein this setting?

My impression of the NCCN [National Comprehensive Cancer Network] guidelines is that theyre there to help us get through the insurance, because most of us are familiar with the datasets. And here [with] a PSA doubling time of less than 2 months in a man who has, by conventional imaging criteria, negative disease, you can use either apalutamide, darolutamide, [or] enzalutamideall category 1 [recommendations].1 But theyre also leaving open the option for other secondary hormonal therapy, allowing for older agents, which I think is not fair in view of all primary and secondary end points being met.

All 3 trialsSPARTAN [NCT01946204], PROSPER [NCT02003924], and ARAMIS [NCT02200614]were identical, with a primary end point looking at metastasis-free survival [MFS] of the agent plus ADT versus placebo, and secondary end points including progression-free survival [PFS], local progression, quality of life, and OS. That was [not a] secondary end point for a lot of the physicians. They still held [off] on it until they heard the final OS data. My prior chair would say, If Im going to treat a patient with an agent for 3 extra years, I need to make sure Im not compromising his quality of life or making his other morbidities worse. But there was a point in the SPARTAN trial [of apalutamide and ADT versus ADT and placebo in patients with nonmetastatic CRPC] that was important for me. It was the only [trial] that looked at the PFS2, which essentially compared starting earlier versus starting later and showed that starting earlier is better.

I think, in the interest of science, we should not stick with, This is what the SPARTAN trial says, this is what the PROSPER trial says, this is what ARAMIS trial says. We have 11 phase 3 trials across the board, across the cancer with novel androgen signaling inhibitors that are all positive. There has been no negative trial, which is phenomenal. The data is superimposable. You cant see a big difference in the efficacy. For efficacy assessment, I dont see a difference between the agents, and I use the datasets across the board. I think they are supportive of each other rather than antagonizing each other.

The [SPARTAN] results are old news now. There was a phenomenal difference in MFS that exceeds the 2-year mark [median MFS, 40.5 months with apalutamide versus 16.2 months without; HR, 0.28; 95% CI, 0.23-0.35; P<.001].2

The new finding that was reported at the [2020] ASCO meeting [was OS], and it was a poster discussion for all 3 [trials]. I like that they made them poster discussions rather than making them big oral discussions. They left oral discussions for more innovative things, [such as] the trials that we do with finding prescriptive markers. A lot of people complained that this was a big deal and should have been more showcased, but I think the fact that they were lumped together and discussed as a success for novel androgen signaling inhibitors is enough, and now we all would agree that their use in this space is valid. The main concern is finding these patients. The OS [had] about a median difference of a little over a year, which is not trivial, for the apalutamide [73.9 versus 59.9 months with ADT/placebo; HR, 0.78; 95% CI, 0.64-0.96; P=.0161].3

I was not involved in the SPARTAN or the ARAMIS trials, but I am an investigator on the PROSPER trial [of enzalutamide and ADT versus ADT and placebo in patients with nonmetastatic CRPC], and I was [included] in this New England Journal of Medicine paper that came out where we showed an OS benefit.4 [The design of the PROSPER trial was] exactly like SPARTAN.

Similar data [were] originally presented. OS difference looking at a year again [67.0 months with enzalutamide vs 56.3 months without; HR, 0.73; 95% CI, 0.61-0.89; P<.001]. The analysis that we saw on SPARTAN is the final analysis with the longest follow-up, but this is not far behind, [with] 48 months of median follow-up.

The ARAMIS trial [of darolutamide and ADT versus ADT and placebo in patients with high-risk nonmetastatic CRPC,] was the one that took us by surprise, because a lot of us were not familiar with this agent. I was seeing it in the background when it was developed, and I could hear Karim Fizazi, MD, PhD, whos a good friend, speaking about it. And I [said], We already have 3, what is this extra fourth going to come through with? And it turns out that they were right in pursuing it. Because they did exactly the same trial as the previous [trials of the other androgen signaling inhibitors], but with an agent that had all the prerequisites to be potentially safer, and they delivered.

The MFS with a short median follow-up [of 17.9 months], looking at about 2 years of difference of MFS [40.4 months with darolutamide versus 18.4 months with placebo], a hazard ratio of 0.41 [95% CI, 0.34-0.50; P<.0001]. Just as a reminder, for the other 2, it was about 0.3. Some people have commented on this, but I would not be able to compare.5

Now, their secondary end points were [more] defiant. At the first presentation, the OS was already starting to look good [with a hazard ratio of 0.71 (95% CI, 0.50-0.99; P<.045)]. It had not [yet] met their threshold, but it was close, and there was a short follow-up compared [with] the other trials.

The time to progression data [show a median time to pain progression of 40.3 months with darolutamide vs 25.4 months without (HR, 0.65; 95% CI, 0.53-0.79; P<.0001)]the other 2 trials also had similar data, which, as I see it, are supportive of each other rather than the inverse. This, for our patients, is a big deal.

Their PFS data [showing a median PFS of 36.8 versus 14.8 months (HR, 0.38; 95% CI, 0.32-0.45; P<.0001)] confirm what I said: superimposable MFS to PFSreinforcing the fact that the addition of a drug [such as] darolutamide, that seems to be safer, adds to these patients more time without need for further interventions and amounts to about 2 years.

The OS at a median follow-up of 29.1 months [was not reached in either arm]; its rather early compared [with] the rest but an obvious improvement here. The hazard ratio was around 0.69 and a P value of 0.003.6 So positive OS data for all 3 trials.

How do the safety profiles of these 3 agents compare?

[In terms of] adverse event reporting [from the PROSPER trial], the main concern, according to them, seems to be grade 3 and above hypertension and some fatigue. I would not pay a lot of attention to what is over grade 3 because when I use a drug for 2 to 3 years, for me even grade 1 and 2 matters. It makes absolute sense to use the least-compromising agent.4

Now, the [ARAMIS safety profile] the winner. They had little adverse events that are treatment related [with darolutamide] [TABLE].5 Its impressive if you look at it versus placebo. And if you want to look at a difference thats at least 2%, I see almost nothing. Its impressive.

When we were working on apalutamide, I got excited because I saw for the first time that 15% of patients were getting a weight decrease. If you look at the data from SPARTAN, it shows up. If you see [the data with] darolutamide, its 3.6%. We started doing some measurements, and its [because of] loss of muscle, and it adds on to the CNS effects. So the falls are not just a result of the CNS effect; its also a lot of muscle weakness, as well.

Overall, how do these 3 trials and drugs compare?

Of course, we shouldnt be [comparing these 3 trials] officially. But there is really no difference between the 3 trials when it comes to the primary and secondary end points. The only difference between the 3 trials with regard to their contact was that, in the apalutamide trial, patients came every month; in the other 2, it was every 4 months. But for MFS and OS, theres no difference between them. They had close hazard ratios.

So we have all [these] agents approved at this pointabiraterone acetate, enzalutamide, apalutamide, and darolutamide. Abiraterone is approved for the hormone-nave metastatic setting, and its also approved for metastatic CRPC; enzalutamide for hormone-nave and nonmetastatic and metastatic CRPC; apalutamide for nonmetastatic CRPC and hormone-nave; and darolutamide for nonmetastatic CRPC. I would argue that for me, these 4 agents have equivalence in their efficacy, and its more a matter of safety.

How does the use of novel imaging affect the duration of treatment and quality of life of these patients?

With the advent of enhanced androgen signaling in the hormone-nave space, I feel that were adding these drugs for an indefinite amount of time. Were going to try to do that with finite-duration hormones, so that we may get the opportunity to prolong the quality of life of the patients. But, as its standing right now, if you do a PET early on in the disease, you may end up treating those men indefinitely.

We know well that if you dont take care to look out for cardiovascular morbidity, bone health, and the like, especially in the older men, you can get a tradeoff thats not to the benefit of the patient. Its a big discussion. But I sometimes say that 1 option is to be more diligent about making sure that the patients are followed at least by their primary care physicians and their cardiologist more carefully.

What are some of the drugs that should be avoided during use with these agents?

Thankfully most of us use electronic prescribing, so we see the drug-drug interactions show up. I dont think we can ever remember all of that by heart.

References:

1. NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. Version 2.2020. May 21, 2020. Accessed August 17, 2020. https://bit.ly/32pmz7H

2. Smith MR, Saad F, Chowdhury S, et al. Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): updated results from the phase III SPARTAN study. Ann Oncol. 2019;30(suppl 5):v325. doi:10.1093/annonc/mdz248

3. Small EJ, Saad F, Chowdhury S, et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2020;30(suppl 15):5516. doi:10.1200/JCO.2020.38.15_suppl.5516

4. Sternberg CN, Fizazi K, Saad F, et al; PROSPER Investigators. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197-2206. doi:10.1056/NEJMoa2003892

5. Fizazi K, Shore ND, Tammela TL, et al; ARAMIS Investigators. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235-1246. doi:10.1056/NEJMoa1815671

6. Fizazi K, Shore ND, Tammela T, et al. Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2020;38(suppl 15):5514. doi:10.1200/JCO.2020.38.15_suppl.5514

Visit link:
Efstathiou Compares the Efficacy and Safety of AR Inhibitors in Nonmetastatic CRPC - Targeted Oncology

Read More..

Contact Us Today

Page 807«..1020..806807808809..820830..»

Home » Page 807